Terms & Conditions  |  Privacy Policy  |  Copyright 2010
Immunodeficiency Clinic, 585 University Avenue, Toronto, ON

Poster Presentations from Recent Research Conferences

2010

Prevalence and associations of infection by herpes simplex virus type 2 (HSV-2) in African-Caribbean women in Toronto

Kaul et al, 19th CAHR Conference, Saskatoon

Shedding of herpes simplex virus in HIV-1-infected individuals receiving suppressive antiretroviral therapy

Tan et al, 19th CAHR Conference, Saskatoon

Cervical dysplasia associated with presence and number of HPV types among a cohort of HIV positive women

Raboud et al, 19th CAHR Conference, Saskatoon

2009

Clinical prediction criteria for neurosyphilis among patients with HIV and syphilis co-infection: findings from a retrospective cohort study

Mishra et al.  5th IAS Conference, July 19-22, 2009, Capetown, South Africa.

The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results

Heera et al.  5th IAS Conference, July 19-22, 2009, Capetown, South Africa.

Incidence of malignancies in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) + optimized background therapy (OBT): 96 week follow-up

Avoub et al.  5th IAS Conference, July 19-22, 2009, Capetown, South Africa.

2008

Fasted Lipid Changes after Administration of Maraviroc or Efavirenz in Combination with Zidovudine and Lamivudine for 48 weeks to Treatment-naïve HIV-infected Patients
DeJesus et al.  15th Conference on Retroviruses and Opportunistic Infections, 2008.

Chromium Supplementation Decreases Insulin Resistance and Trunk Fat
Aghdassi et al.  15th Conference on Retroviruses and Opportunistic Infections, 2008.

2006

Tipranavir Achieves Twice the Rate of Treatment Response and Prolongs Durability of Response vs Comparator PI in ART-experienced Patients, Independent of Baseline CD4 Cell Count or Viral Load: Week 48 RESIST 1 and 2 Combined Analyses
Katlama et al.  13th Conference on Retroviruses and Opportunistic Infections, 2006.

2005

A Randomized Placebo Controlled Trial of Rosiglitazone for the Treatment of HIV Lipodystrophy
Cavalcanti et al.  12th Conference on Retroviruses and Opportunistic Infections, 2005.

CTN 164: A Prospective Randomized Trial of Structured Treatment Interruption vs Immmediate Switching in HIV-infected Patients Experiencing Virologic Failure on HAART
Walmsley et al.  12th Conference on Retroviruses and Opportunistic Infections, 2005.

24-Week RESIST Study Analyses: the Efficacy of Tipranavir/Ritonavir Is Superior to Lopinavir/Ritonavir, and the TPV/r Treatment Response is Enhanced by Inclusion of Genotypically Active Antiretrovirals in the Optimized Background Regimen
Cooper et al.  12th Conference on Retroviruses and Opportunistic Infections, 2005.

Anal Cancer Screening: Test Characteristics of Cytology and Oncogenic HPV testing for the Detection of Anal Dysplasia
Salit et al.  12th Conference on Retroviruses and Opportunistic Infections, 2005.

Selected Research Publications

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

Walmsley et al.  J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):367-74.

Is there a reservoir of sub-clinical lymphogranuloma venereum and non-LGV Chlamydia trachomatis infection in men who have sex with men?

Tinmouth et al.  Int J STD AIDS. 2008 Dec;19(12):805-9.

A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy.

Walmsley et al.  HIV Clin Trials. 2008 Sep-Oct;9(5):314-23

Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.

Wright et al.  HIV Clin Trials. 2008 Mar-Apr;9(2):73-82.

Evaluation of Stool frequency and stool form as measures of HIV-related diarrhea.

Tinmouth et al.  HIV Clin Trials. 2007 Nov-Dec;8(6):421-8.

Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study.

Prior et al.  Osteoporos Int. 2007 Oct;18(10):1345-53. Epub 2007 Jul 31.

A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

Cavalcanti et al.  J Infect Dis. 2007 Jun 15;195(12):1754-61. Epub 2007 May 2.

A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome.

Austin et al.  Eur J Clin Nutr. 2006 Nov;60(11):1266-76. Epub 2006 May 24

The effect of dairy product ingestion on human immunodeficiency virus-related diarrhea in a sample of predominantly gay men: a randomized, controlled, double-blind, crossover trial.

Tinmouth et al.  Arch Intern Med. 2006 Jun 12;166(11):1178-83.